Study Title and Description
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
Key Questions Addressed
|6||Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?|
Primary Publication Information
|Title||Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.|
|Author||Brown A., Hézode C., Zuckerman E., Foster GR., Zekry A., Roberts SK., Lahser F., Durkan C., Badshah C., Zhang B., Robertson M., Wahl J., Barr E., Haber B.|
|Country||Imperial College Healthcare NHS Trust, London, UK.|
Pubmed ID: 29152828
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-9
Results & Comparisons
No Results found.